Novartis signs gene therapy deal with Voyager for $100 mln upfront (updated)

Voyager Therapeutics

02/01/2024 12:36

(Adds shares in paragraph 2 and details throughout)
       Jan 2 (Reuters) - Voyager Therapeutics  VYGR.O  said on
Tuesday Novartis  NOVN.S  would pay $100 million upfront as part
of a licensing deal to develop gene therapy candidates.
    Voyager, whose shares jumped 35% in premarket trading, would
provide Novartis a target-exclusive license to access its
RNA-based screening platform and advance a gene therapy
candidate in pre-clinical stage for a genetic disorder known as
Huntington's disease (HD). 
    The gene therapies developer is also eligible to receive up
to $1.2 billion in certain milestone payments, as well as tiered
royalties on global net sales of products incorporating its
RNA-based screening platform.

 (Reporting by Pratik Jain in Bengaluru; Editing by Shilpi
Majumdar)
 ((Pratik.Jain@thomsonreuters.com;))